Skip to main content

Table 3 Most frequent TEAEs (> 5% of subjects) in double-blind period up to 12 weeks

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Preferred term Placebo (N = 27) Namilumab
20 mg (N = 28) 80 mg (N = 25) 150 mg (N = 28)
Nasopharyngitis 5 (18.5) 5 (17.9) 1 (4.0) 4 (14.3)
Dyspnoea 0 1 (3.6) 2 (8.0) 3 (10.7)
Bronchitis 2 (7.4) 1 (3.6) 1 (4.0) 1 (3.6)
Headache 1 (3.7) 1 (3.6) 3 (12.0) 0
Upper respiratory tract infection 0 0 2 (8.0) 1 (3.6)
Rheumatoid arthritis 0 2 (7.1) 2 (8.0) 0
Hypertension 0 0 0 2 (7.1)
Laryngitis 0 0 2 (8.0) 0
Menorrhagia 0 2 (7.1) 0 0
Urticaria 0 2 (7.1) 0 0
  1. Values are n (%). TEAE treatment-emergent adverse event
\